Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $20.78, for a total value of $207,800.00. Following the transaction, the director now directly owns 49,309 shares in the company, valued at approximately $1,024,641.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of AMPH stock traded up $0.05 during trading on Thursday, reaching $20.90. 222,463 shares of the company’s stock were exchanged, compared to its average volume of 184,544. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The stock has a market capitalization of $995.14 million, a PE ratio of 99.52 and a beta of 1.35. Amphastar Pharmaceuticals Inc has a twelve month low of $17.45 and a twelve month high of $25.43. The business has a fifty day moving average price of $20.24.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, August 7th. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.05. The business had revenue of $79.00 million for the quarter, compared to analyst estimates of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 EPS. Sell-side analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.15 EPS for the current fiscal year.
Several research firms have weighed in on AMPH. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, August 7th. Wells Fargo & Co set a $29.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. BidaskClub raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $24.64.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Featured Story: What is the significance of the death cross?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.